ADRA2C and neoplasm: These correlations suggest that ADRA2C might serve as a co-factor in the function of immune checkpoint agents in tumor immunotherapy, especially in ACC, BLCA, COAD, HNSC, KICH, LGG, LUSC, OV, SARC, SKCM, STAD, and UVM.